Literature DB >> 1788493

Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing.

E R Swenson1, K L Leatham, R C Roach, R B Schoene, W J Mills, P H Hackett.   

Abstract

The efficacy of carbonic anhydrase (CA) inhibitors in amelioration of periodic breathing during sleep at high altitude is not fully understood. Although CA is present in a number of tissues, we hypothesized that selective renal CA inhibition without physiologically important inhibition of other tissue CA, may be sufficient alone by its generation of a mild metabolic acidosis to stimulate ventilation and prevent periodic breathing. We studied benzolamide (3 mg/kg), a selective inhibitor of renal CA, in 4 climbers on ventilation and ventilatory responses at sea level and on arterial O2 saturation (SaO2%) and periodic breathing during sleep at altitude. At sea level, ventilation increased and PaO2 rose accompanied by a mild metabolic acidosis. The isocapnic hypoxic ventilatory response was unchanged but the hyperoxic hypercapnic ventilatory response rose 40%. At high altitude (4400 m), daytime SaO2% improved from 81 to 85 and venous plasma HCO3- fell from 18.9 to 14.8 mM. During sleep, mean SaO2% rose from 76 to 80 and periodic breathing decreased 75%. We conclude that metabolic acidosis occurring with all CA inhibitors is one of the major stimulant actions of these drugs on ventilation while awake and during sleep at high altitude.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1788493     DOI: 10.1016/0034-5687(91)90104-q

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  11 in total

1.  Acetazolamide and cerebrovascular function at high altitude.

Authors:  Luc J Teppema; Remco R Berendsen
Journal:  J Physiol       Date:  2012-06-15       Impact factor: 5.182

Review 2.  Impact of concomitant medications on obstructive sleep apnoea.

Authors:  Ingrid Jullian-Desayes; Bruno Revol; Elisa Chareyre; Philippe Camus; Céline Villier; Jean-Christian Borel; Jean-Louis Pepin; Marie Joyeux-Faure
Journal:  Br J Clin Pharmacol       Date:  2016-11-24       Impact factor: 4.335

Review 3.  High altitude medicine for family physicians.

Authors:  S J McMurray
Journal:  Can Fam Physician       Date:  1994-04       Impact factor: 3.275

4.  Sleep and Breathing at High Altitude.

Authors:  Himanshu Wickramasinghe; James D. Anholm
Journal:  Sleep Breath       Date:  1999       Impact factor: 2.816

5.  Molecular Mechanisms of Transcription Factor 4 in Pitt Hopkins Syndrome.

Authors:  Matthew D Rannals; Brady J Maher
Journal:  Curr Genet Med Rep       Date:  2017-02-11

6.  The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis.

Authors:  Yue-Nan Ni; Huan Yang; Robert Joseph Thomas
Journal:  J Clin Sleep Med       Date:  2021-06-01       Impact factor: 4.324

7.  Ventilatory oscillations at exercise: effects of hyperoxia, hypercapnia, and acetazolamide.

Authors:  Eric Hermand; François J Lhuissier; Julie Larribaut; Aurélien Pichon; Jean-Paul Richalet
Journal:  Physiol Rep       Date:  2015-06

8.  The noncarbonic anhydrase inhibiting acetazolamide analog N-methylacetazolamide reduces the hypercapnic, but not hypoxic, ventilatory response.

Authors:  Luc J Teppema; Erik R Swenson
Journal:  Physiol Rep       Date:  2015-08

9.  Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level.

Authors:  David J Collier; Chris B Wolff; Anne-Marie Hedges; John Nathan; Rod J Flower; James S Milledge; Erik R Swenson
Journal:  Pharmacol Res Perspect       Date:  2016-05-19

10.  Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide.

Authors:  Michael F Harrison; Paul J Anderson; Jacob B Johnson; Maile Richert; Andrew D Miller; Bruce D Johnson
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.